NCT04330664

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

A Phase 1/2 Trial of MRTX849 in Combination With TNO155 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL 2

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 86 (actual)
• Sponsor: Mirati Therapeutics Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors that have a KRAS G12C mutation.

Detailed description

This study will evaluate the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 is an orally available small molecule inhibitor of KRAS G12C and TNO155 is a selective, orally bioavailable allosteric inhibitor of wild-type SHP2. This study was terminated prior to phase 2 initiating. Only phase 1 of the study was conducted.

Conditions

• Advanced Cancer
• Metastatic Cancer
• Malignant Neoplastic Disease

Interventions

Type	Name	Description
DRUG	MRTX849	KRAS G12C Inhibitor
DRUG	TNO155	SHP2 Inhibitor

Timeline

• Start date: 2020-04-07
• Primary completion: 2022-07-29
• Completion: 2025-02-24
• First posted: 2020-04-01
• Last updated: 2025-04-04

Locations

17 sites across 1 country: United States

Regulatory

• FDA-regulated drug study